Acumen Pharmaceuticals closes $35.8M financing, completes ALTITUDE-AD enrollment
Acumen Pharmaceuticals ended 2025 with $116.9 million in cash and marketable securities and secured a $35.75 million private placement to fund its EBD program. The company completed enrollment in its Phase II ALTITUDE-AD trial while reporting a $121.3 million net loss and $104.9 million R&D spend.
1. Cash Position and Fundraising
Acumen ended 2025 with $116.9 million in cash and marketable securities and completed a $35.75 million private placement on March 16, 2026 to support its Enhanced Brain Delivery program, extending its cash runway into early 2027.
2. Clinical Trial Progress
The company finished enrollment in the Phase II ALTITUDE-AD trial targeting synaptic toxic amyloid-beta oligomers, with participants rolling over into a 12-month open-label extension without protocol alterations and demonstrating strong retention and safety tolerability.
3. 2025 Financial Results
Acumen reported a net loss of $121.3 million for 2025, driven by $104.9 million in R&D expenses related to its ALTITUDE-AD trial and EBD research, while general and administrative costs fell to $18.9 million following cuts in recruiting, insurance, and consulting.